|Day Low/High||6.08 / 6.22|
|52 Wk Low/High||3.71 / 18.98|
Aurora is trying to ride the momentum of Aphria's earnings report and jump in front of other potential strong reports.
Yesterday and most of last week I have been expanding my Canopy Growth long investment position (the stock is on my Best Ideas List). CGC (+6%) and the other pot stocks should thrive today after the Aurora Cannabis revised upward guidance (its share...
Analysts say nation will turn a new leaf, changing federal law within a few years, as cannabis industry expected to grow big time over next decade.
Is prohibition the real factor propping up projections for demand and pricing in the cannabis market?
While the cannabis company's stock is sliding on its year-end report, at least one analyst sees a long-term buying opportunity.
Overall, I don't like the action I'm seeing on my screens. I've been a heavy net seller as I cut positions that are showing some relative weakness.
CGC has the best chance to transition to broader success should the U.S. ever go the route of legalization beyond the state level.
I just mentioned one of my partners here at TheStreet, now let's wheel about and mention 'Sarge' Guilfoyle who sat in this very seat yesterday. In the Stocks Under $10 portfolio, he's been the man in charge of the weed stocks positions and he's done...
The pot sector has been weak recently. I own a very small long position in which is -$1 to under $44/share (which was added to my Best Ideas List on January 2, 2019 at $27.75) As I mentioned I wasn't willing to pay up for recently and, in general, ...
Revenue is where it's at for cannabis in 2019.
A huge week is coming up for these well-known stocks.
Short interest is back in the low single digits while Tilray still enjoys one of the smallest floats for a cannabis company.
Apparently, this game is all about growth right now. It certainly is not about margins.
Some momentum movers are becoming extended and have seen profit-taking Monday.
On Wednesday I explained why I would not buy the gap higher in Aurora Cannabis . There is a tendency for traders, in particular, to buy the latest shiny object and to ask questions later; after all the price momentum is a tradeable thing of beauty t...
Assessing Aurora and its peers, strictly on the numbers.
In this day and age, companies must be 'disruptors' or get left in the dust.
Peltz's addition should pacify a persistent critique of the company.
* The consensus is growing more consensus! * The notion of risk has left the Exchange's building * The last hour of trading uncharacteristically weak Today's session was another one supported by good overall breadth (2,154/786 on the NYSE). Howeve...
* Nelson Peltz's imprimatur has value * But, from my perch, not $1 billion of value! "Buy Aurora Cannabis . Buy it because Nelson Peltz is now an advisor to the company with options to buy 20 million shares at a minimum. Buy it because Nelson's con...
Aurora Cannabis' hiring of deal maker Nelson Peltz opens up a wealth of new possibilities for the Canadian pot company.
I know that Nelson is fascinated by the medicinal properties chiefly as a replacement for opioids, the scourge of this country.
Aurora's prominent partner could be cannabis' key to breaking into consumer segments.
The plan is for Peltz to help the firm in maximizing potential markets to target.
Themes like cannabis tend to persist longer than many think they will.